Market Pulse Archives

Oct. 22, 2020, 4:38 p.m. EDT

Gilead's stock rises as FDA formally approves remdesivir

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Gilead Sciences Inc. (GILD)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Gilead Sciences Inc. /zigman2/quotes/210293917/composite GILD -0.70% jumped 4.1% in after-hours trading on Thursday after it said the Food and Drug Administration (FDA) had approved Veklury, its COVID-19 treatment, for patients who have been hospitalized with COVID-19 infections. The antiviral drug, until now called remdesivir, in early May had received an emergency use authorization (EUA), which is a less rigorous type of regulatory authorization used during public-health emergencies. Veklury is the first COVID-19 therapy to receive a full FDA approval during the pandemic and has been considered the standard of care when it comes to treating hospitalized patients since it received emergency authorization. The EUA and the approval are based on a series of clinical studies that found Veklury can reduce recovery time when compared to placebo. It can also reduce disease progression among severely ill patients who require oxygen. Gilead announced in August that it plans to seek full approval for the drug. As part of Thursday's announcement, Gilead said the FDA had also authorized the drug for pediatric COVID-19 patients who are 11 years old or younger and who have been hospitalized. Gilead's stock is down 6.6% for the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.60% is up 6.3%.

US : U.S.: Nasdaq
$ 70.15
-0.50 -0.70%
Volume: 3.34M
Nov. 30, 2021 1:32p
P/E Ratio
Dividend Yield
Market Cap
$88.62 billion
Rev. per Employee
-74.55 -1.60%
Volume: 1.64B
Nov. 30, 2021 1:32p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.